Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patients receiving moderately to highly emetogenic chemotherapy
- At a dose of 20 μg/kg, Palonosetron, administered as a single dose, is as effective as ondansetron 0.15 mg/kg given three times a day to a maximum dose of 32mg
- No safety concerns were raised by the study
Lugano, Switzerland, October 23, 2014 – Helsinn Group, the company focused on building quality cancer care, present data at the International Society of Paediatric Oncology (SIOP) congress establishing that palonosetron, at a dose 20 μg/kg, is a valuable and efficacious treatment option for chemotherapy-induced nausea and vomiting (CINV) in pediatric patients up to 17 years of age. CINV is a common and distressing side-effect of chemotherapy which, if inadequately controlled, can lead to dehydration, electrolyte imbalance and hospitalization.
The data [presented at the SIOP congress in Toronto, 22-24 October, today, October 23rd] derive from a large randomized trial and establish that the investigated higher dose palonosetron (20 μg/kg), given as a single dose, demonstrated similar efficacy to multiple daily administrations of ondansetron up to 32mg/day (considered current standard of care) in the prevention of CINV in pediatric patients receiving highly emetogenic chemotherapy. The results also indicated that the 20 μg/kg dose of palonosetron does not require dose adjustment according to patient age. No safety concerns were raised by the study. Therefore, the study met its primary objective demonstrating the non-inferiority of palonosetron compared with ondansetron in pediatric patients up to 17 years of age.
In May 2014, the intravenous formulation of palonosetron was approved by the FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in pediatric patients aged from one month up to 17 years. This was the first such approval of a product for patients under six months. The incidence of cancer in children peaks within the first year of life, so the approval increases the scope of treatment options to improve the quality of life for children undergoing cancer chemotherapy.
Helsinn’s Chief Executive Officer, Riccardo Braglia, commented: “These trial data demonstrate that palonosetron at high single dose represents a compelling treatment option for CINV in children and small infants. CINV is a distressing and dangerous condition and particularly trying for children undergoing chemotherapy, their families and caregivers.
“Helsinn is committed to offering the highest-quality supportive care to people undergoing cancer treatment and is pleased to see that palonosetron is validated by this comprehensive study.”
This was a Phase III, double-blind, double-dummy, randomized, parallel group stratified study of 502 patients randomized to treatment across 59 clinical centers, designed to show the non-inferiority of two dose levels of palonosetron (10 μg/kg and 20 μg/kg) compared with ondansetron (0.15 mg/kg every 4 hours/day for a maximum of 32mg/day), which is considered as standard therapy.
The primary objective of the trial was to demonstrate the non-inferiority of palonosetron to ondansetron, with a delta margin of -15%, in terms of complete response rates (no vomiting or recue medication) during the 24 hour period after chemotherapy administration (acute phase).
Secondary objectives included complete response rate at 25–120 hours and 0–120 hours after chemotherapy administration (delayed and overall phase respectively). The principal analysis population was the full analysis dataset (FAS) including 493 patients, aged from 64 days to 16.9 years. Of particular note, 45 patients were below age 2 years.
The patients were randomized to one of three groups: low-dose palonosetron (10 μg/kg; FAS n=166 patients), high-dose palonosetron (20 μg/kg; FAS n=165) and ondansetron (maximum dose 32mg/kg/day; FAS n=162).
The complete response rate (95% CI) during the acute phase was 54.2% (46.3%–61.9%) and 59.4% (51.5%–66.9%) for the low- and high-dose palonosetron groups, respectively, and 58.6% (50.6%–66.2%) in the ondansetron group. This confirmed the non-inferiority between the high-dose 20 μg/kg of palonosetron and ondansetron.
The pharmacokinetic profile of palonosetron after a 15 minute infusion was comparable for all age groups and for both dose levels confirming no need for dose adjustment according to patient age.
Considering the delayed phase, the complete response rate for palonosetron 20µg/kg was 38.8%, for ondansetron the complete response rate during this period was 28.9%. The pattern of results for complete response during the overall phase was consistent with that observed in the delayed phase rate for palonosetron 20µg/kg was 32.7%, and for ondansetron it was 24.1%.
The type and frequency of treatment-emergent adverse events (TEAE) were consistent across the palonosetron 10 µg/kg and 20 µg/kg groups and the ondansetron group. No incremental toxicity was apparent in patients treated with the higher (20 µg/kg) palonosetron dose compared with those treated with the lower (10 µg/kg) dose. Throughout the study, no patients had drug-related TEAEs with fatal outcome or discontinued the study due to drug-related TEAEs. The safety profile of palonosetron in this pediatric study is consistent with the established information collected during previous clinical experiences. All withdrawals and/or deaths were unrelated to the study drug.
Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 receptor antagonist developed for the prevention of CINV in patients with cancer. Patients received palonosetron (low-dose: 10 µg/kg, maximum dose 0.75 mg; high-dose: 20 µg/kg, maximum dose 1.5 mg) or ondansetron (3 x 0.15mg/kg, maximum dose 32 mg).
About ALOXI® (palonosetron HCl)
Indication in Adults
ALOXI injection is used in adults to help prevent nausea and vomiting when it happens right away or later (up to five days) with certain anti-cancer medicines (chemotherapy).
Indication in Pediatrics
ALOXI is used in children 1 month old to less than 17 years of age to help prevent nausea and vomiting that happens right away (up to 24 hours) with certain anti-cancer medicines (chemotherapy).
Important Safety Information
- ALOXI can cause allergic reactions that can be serious. Tell your doctor or nurse right away if you have any of these following symptoms of a serious allergic reaction: hives, swelling of the face, trouble breathing and chest pain
- The most common side effects of ALOXI in adults are headache and constipation
- Tell your doctor or nurse if you are taking other medications or if you are pregnant or breastfeeding or plan to become pregnant or breastfeed
ALOXI is available by prescription only.
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the U.S. and a Representative Office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn’s products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
Further information on Helsinn Group is available at www.helsinn.com
For more information, please contact:
Head of Communication & Press Office
Tel: +41 91-985-21-21
For media/external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton
Tel: +44 (0)203 709 5700